Phaseline

Companies › Bantam Pharmaceuticals

Bantam Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BTM-3566–Phase 1Lymphoma, B-Cell; Advanced Solid TumorsFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06792734BTM-3566Phase 1Lymphoma, B-CellOncologyFeb 2027
NCT07266285BTM-3566Phase 1Advanced Solid TumorsOncologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.